News
XFOR
1.185
-0.84%
-0.010
X4 Pharmaceuticals: PDUFA Excitement Ahead
X4 Pharmaceuticals, Inc. Is awaiting an FDA decision on its lead molecule mavorixafor for the treatment of WHIM syndrome. X4's lead molecule is a powerful immune system booster with potential in treating rare immunodeficiency. The company's financial position is challenging with increasing expenses and a significant accumulated deficit.
Seeking Alpha · 3d ago
Weekly Report: what happened at XFOR last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at XFOR last week (0401-0405)?
Weekly Report · 04/08 09:46
X4 Pharmaceuticals Updates Corporate Presentation Online
TipRanks · 04/01 13:32
Weekly Report: what happened at XFOR last week (0325-0329)?
Weekly Report · 04/01 09:46
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
X4 Pharmaceuticals will participate in the Needham 23rd Annual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium in 2024. X4 is a company driven to improve the lives of people with rare diseases of the immune system. Management will be participating in both events.
Barchart · 04/01 07:00
Biotech Stocks Facing FDA Decision In April 2024
NASDAQ · 03/28 14:54
Weekly Report: what happened at XFOR last week (0318-0322)?
Weekly Report · 03/25 09:47
X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence
TipRanks · 03/23 06:01
X4 Pharmaceuticals Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 19:04
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
Benzinga · 03/22 18:54
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects
TipRanks · 03/22 10:28
12 Health Care Stocks Moving In Thursday's Intraday Session
10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. Monogram Orthopaedics stock rose 28.74% and X4 Pharmaceuticals stock increased by 21.61%. Tourmaline Bio ( NASDAQ:TRML) shares decreased by 40.6% during the regular session to $26.54.
Benzinga · 03/21 17:31
XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023
X4 Pharmaceuticals reported earnings per share of -10 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -15 cents. X4 reported results for the last quarter of 2013.
Investorplace · 03/21 14:53
PHIO and MGRM among healthcare movers
On the Move PHIO and MGRM among healthcare movers. S&P 500 Health Care Sector +0.16% to 1699.95. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. Nortech Systems and X4 Pharmaceuticals are among the gainers.
Seeking Alpha · 03/21 14:12
X4 Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
X4 Pharmaceuticals Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $19.13 million. Shares had risen by 21.6% this quarter. The company's reported EPS was a loss of 10 cents.
Reuters · 03/21 13:32
Earnings Scheduled For March 21, 2024
Creative Realities is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Welltower is likely to report earnings for its fourth quarter. Accenture is also projected to report before the bell. Other companies expected to be reporting before the Bell include Shoe Carnival, Y.M.C. And Y.T.
Benzinga · 03/21 10:15
Recap: X4 Pharmaceuticals Q4 Earnings
X4 Pharmaceuticals reported its Q4 earnings on March 21. The company beat estimates by 33.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.14 and was followed by a 5.0% drop in share price.
Benzinga · 03/21 10:15
X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05
X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05. X4 believes it has sufficient funds to support company operations into 2025. The company had $115.2 million in cash and cash equivalents as of December 31, 2023.
Seeking Alpha · 03/21 10:08
X4 Pharmaceuticals Q4 EPS $(0.10) Beats $(0.15) Estimate
Benzinga · 03/21 10:02
More
Webull provides a variety of real-time XFOR stock news. You can receive the latest news about X4 Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About XFOR
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.